3D Cell Culture Market

Executive Summary

3D Cell Culture Market was valued at US $1.93 billion in 2021 and is projected to grow at 10.71% CAGR over the forecast period to reach US $3.55 billion by 2027. 3D Cell Culture Market represented US $0.35 billion opportunity over 2019-2021 and estimated to create US $1.62 billion opportunity in 2027 over 2021.

3D Cell Culture from Consainsights analyses the 3D Cell Culture Market in the Life Sciences industry over the forecast period to 2027.

3D Cell Culture research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

3D Cell Culture segmentation includes Product, Application, End User, Region and Geography.

Based on the Product, the 3D Cell Culture analysis covers Scaffold-Based 3D Cell Cultures, Scaffold-Free 3D Cell Cultures, Microfluidics-Based 3D Cell Cultures, Magnetic & Bioprinted 3D Cell Cultures.

In Product segment, Scaffold-Based 3D Cell Cultures segment has highest cagr growth of 9.47%.

Based on the Application, the 3D Cell Culture analysis covers Cancer & Stem Cell Research, Drug Discovery & Toxicology Testing, Tissue Engineering & Regenerative Medicine.

In Application segment, Cancer & Stem Cell Research segment has highest cagr growth of 9.47%.

Based on the End User, the 3D Cell Culture analysis covers Pharmaceutical & Biotechnology Companies, Research Institutes, Cosmetics Industry, Other End Users.

In End User segment, Pharmaceutical & Biotechnology Companies segment has highest cagr growth of 9.47%.

Based on the Region, the 3D Cell Culture analysis covers North America, Europe, Asia Pacific, Rest of the World.

In Region segment, North America segment has highest cagr growth of 9.47%.

Based on the region, the 3D Cell Culture analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza Group, REPROCELL, Biotek LLC, Emulate, Inc., CN Bio Innovations Limited, Hamilton Company, Insphero AG, Kirkstall, Ltd., MIMETAS BV, TissUse GmbH, Synthecon Incorporated, QGel SA, Other Key Players and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Scaffold-Based 3D Cell Cultures segment has the highest revenue of US $0.80 billion and is expected to grow at CAGR of 9.47% by 2027 Scaffold-Based 3D Cell Cultures segment has highest cagr growth of 9.47%.

Scaffold-Based 3D Cell Cultures

Scaffold-Based 3D Cell Cultures segment was valued at US $0.66 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $1.48 billion by 2027. Scaffold-Based 3D Cell Cultures segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.68 billion opportunity in 2027 over 2021.

Scaffold-Free 3D Cell Cultures

Scaffold-Free 3D Cell Cultures segment was valued at US $0.40 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.91 billion by 2027. Scaffold-Free 3D Cell Cultures segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.42 billion opportunity in 2027 over 2021.

Microfluidics-Based 3D Cell Cultures

Microfluidics-Based 3D Cell Cultures segment was valued at US $0.33 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.75 billion by 2027. Microfluidics-Based 3D Cell Cultures segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.34 billion opportunity in 2027 over 2021.

Magnetic & Bioprinted 3D Cell Cultures

Magnetic & Bioprinted 3D Cell Cultures segment was valued at US $0.18 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.40 billion by 2027. Magnetic & Bioprinted 3D Cell Cultures segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.18 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Cancer & Stem Cell Research segment has the highest revenue of US $0.88 billion and is expected to grow at CAGR of 9.47% by 2027 Cancer & Stem Cell Research segment has highest cagr growth of 9.47%.

Cancer & Stem Cell Research

Cancer & Stem Cell Research segment was valued at US $0.72 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $1.62 billion by 2027. Cancer & Stem Cell Research segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.74 billion opportunity in 2027 over 2021.

Drug Discovery & Toxicology Testing

Drug Discovery & Toxicology Testing segment was valued at US $0.36 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.81 billion by 2027. Drug Discovery & Toxicology Testing segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Tissue Engineering & Regenerative Medicine

Tissue Engineering & Regenerative Medicine segment was valued at US $0.49 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $1.11 billion by 2027. Tissue Engineering & Regenerative Medicine segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Pharmaceutical & Biotechnology Companies segment has the highest revenue of US $0.82 billion and is expected to grow at CAGR of 9.47% by 2027 Pharmaceutical & Biotechnology Companies segment has highest cagr growth of 9.47%.

Pharmaceutical & Biotechnology Companies

Pharmaceutical & Biotechnology Companies segment was valued at US $0.67 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $1.51 billion by 2027. Pharmaceutical & Biotechnology Companies segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.69 billion opportunity in 2027 over 2021.

Research Institutes

Research Institutes segment was valued at US $0.57 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $1.28 billion by 2027. Research Institutes segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.59 billion opportunity in 2027 over 2021.

Cosmetics Industry

Cosmetics Industry segment was valued at US $0.33 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.74 billion by 2027. Cosmetics Industry segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.34 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $0.01 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.01 billion by 2027. Other End Users segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $0.79 billion and is expected to grow at CAGR of 9.47% by 2027 North America segment has highest cagr growth of 9.47%.

North America

North America segment was valued at US $0.64 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $1.46 billion by 2027. North America segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.67 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.36 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.81 billion by 2027. Europe segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.38 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.85 billion by 2027. Asia Pacific segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.39 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $0.19 billion in 2019 and is projected to grow at 9.47% CAGR over the forecast period to reach US $0.43 billion by 2027. Rest of the World segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.20 billion opportunity in 2027 over 2021.